Lynn Sadowski Mason
Hoofd Techniek/Wetenschap/O&O bij Eterna Therapeutics LLC
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Charles Cherington | M | 61 |
Eterna Therapeutics LLC
Eterna Therapeutics LLC Pharmaceuticals: MajorHealth Technology Part of Eterna Therapeutics, Inc., Eterna Therapeutics LLC is a clinical-stage biopharmaceutical company based in New York, NY. The company is focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer. Eterna Therapeutics is committed to developing irx-2, a novel cytokine-based therapy, to treat patients with cancer. The active constituents of irx-2, namely interleukin-2 (il-2) and other key cytokines, are postulated to signal, enhance and restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. Eterna Therapeutics is a late clinical-stage biopharmaceutical company focused on il-2 cytokine-based therapies in treating patients with cancer. Eterna Therapeutics was acquired by NTN Buzztime, Inc. on March 25, 2021 for $213.30 million. | 6 jaar |
Peter Arduini | M | 59 | 8 jaar | |
Theodore Samuels | M | 69 | 7 jaar | |
Nicholas Singer | M | 44 |
Eterna Therapeutics LLC
Eterna Therapeutics LLC Pharmaceuticals: MajorHealth Technology Part of Eterna Therapeutics, Inc., Eterna Therapeutics LLC is a clinical-stage biopharmaceutical company based in New York, NY. The company is focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer. Eterna Therapeutics is committed to developing irx-2, a novel cytokine-based therapy, to treat patients with cancer. The active constituents of irx-2, namely interleukin-2 (il-2) and other key cytokines, are postulated to signal, enhance and restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. Eterna Therapeutics is a late clinical-stage biopharmaceutical company focused on il-2 cytokine-based therapies in treating patients with cancer. Eterna Therapeutics was acquired by NTN Buzztime, Inc. on March 25, 2021 for $213.30 million. | 1 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
James Cornelius | M | 81 | 10 jaar | |
Mark Leuchtenberger | M | 67 |
Eterna Therapeutics LLC
Eterna Therapeutics LLC Pharmaceuticals: MajorHealth Technology Part of Eterna Therapeutics, Inc., Eterna Therapeutics LLC is a clinical-stage biopharmaceutical company based in New York, NY. The company is focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer. Eterna Therapeutics is committed to developing irx-2, a novel cytokine-based therapy, to treat patients with cancer. The active constituents of irx-2, namely interleukin-2 (il-2) and other key cytokines, are postulated to signal, enhance and restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. Eterna Therapeutics is a late clinical-stage biopharmaceutical company focused on il-2 cytokine-based therapies in treating patients with cancer. Eterna Therapeutics was acquired by NTN Buzztime, Inc. on March 25, 2021 for $213.30 million. | 2 jaar |
Robert Bertolini | M | 61 | 4 jaar | |
Lewis B. Campbell | M | 77 | 18 jaar | |
Matthew Emmens | M | 72 | 4 jaar | |
Ronald Guido | M | 67 |
Eterna Therapeutics LLC
Eterna Therapeutics LLC Pharmaceuticals: MajorHealth Technology Part of Eterna Therapeutics, Inc., Eterna Therapeutics LLC is a clinical-stage biopharmaceutical company based in New York, NY. The company is focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer. Eterna Therapeutics is committed to developing irx-2, a novel cytokine-based therapy, to treat patients with cancer. The active constituents of irx-2, namely interleukin-2 (il-2) and other key cytokines, are postulated to signal, enhance and restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. Eterna Therapeutics is a late clinical-stage biopharmaceutical company focused on il-2 cytokine-based therapies in treating patients with cancer. Eterna Therapeutics was acquired by NTN Buzztime, Inc. on March 25, 2021 for $213.30 million. | 3 jaar |
Luba Greenwood | F | 45 | 1 jaar | |
John Tsai | M | 57 | 11 jaar | |
Douglas Manion | M | 64 | 11 jaar | |
David Feltquate | M | - | 3 jaar | |
Mary Kay Turner | F | - | 6 jaar | |
John Houston | M | 64 | 6 jaar | |
Sabine Maier | F | - | - | |
Kevin Trapp | M | - | 2 jaar | |
Joshua Reed | M | 51 | 2 jaar | |
Nancy Phelan | F | 55 | 5 jaar | |
Susan Miller | F | 44 | - | |
Joseph Eid | M | 56 | 4 jaar | |
Ronald Peck | M | 58 | 4 jaar | |
Charles Conway | M | 62 | 17 jaar | |
J. Brian Stalter | M | 52 | 11 jaar | |
Michael Gottlieb | M | 54 | - | |
Steve Innaimo | M | - | 23 jaar | |
Sanjay Keswani | M | 54 | 4 jaar | |
Jill Andersen | F | 51 | 4 jaar | |
JC Xu | M | 60 | 3 jaar | |
James Cassidy | M | 65 | 3 jaar | |
Richard Isaac Simtob | M | 54 | - | |
Ronald Cooper | M | 61 | 7 jaar | |
Linda Kozick | F | 66 | 4 jaar | |
Ken Dominski | M | - | - | |
Francis Cuss | M | 70 | 14 jaar | |
Yiannis A. Monovoukas | M | 62 | - | |
George Denny | M | - | - | |
Matt Roden | M | 53 | 4 jaar | |
Andres Gutiérrez | M | 63 | 3 jaar | |
Allen Wolff | M | 52 | - | |
Anil Kapur | M | 54 | 2 jaar | |
Michelle Werner | F | 48 | 10 jaar | |
Suketu Upadhyay | M | 55 | 3 jaar | |
Vladimir Coric | M | 53 | 8 jaar | |
Julie Hambleton | M | 66 | 1 jaar | |
Ranya Dajani | F | - | - | |
Michael Giordano | M | 66 | 18 jaar | |
Monil Shah | M | - |
Eterna Therapeutics LLC
Eterna Therapeutics LLC Pharmaceuticals: MajorHealth Technology Part of Eterna Therapeutics, Inc., Eterna Therapeutics LLC is a clinical-stage biopharmaceutical company based in New York, NY. The company is focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer. Eterna Therapeutics is committed to developing irx-2, a novel cytokine-based therapy, to treat patients with cancer. The active constituents of irx-2, namely interleukin-2 (il-2) and other key cytokines, are postulated to signal, enhance and restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. Eterna Therapeutics is a late clinical-stage biopharmaceutical company focused on il-2 cytokine-based therapies in treating patients with cancer. Eterna Therapeutics was acquired by NTN Buzztime, Inc. on March 25, 2021 for $213.30 million. | 1 jaar |
Mohamed Ragab | M | - | - | |
Jonathan Yingling | M | 55 | 2 jaar | |
Bernadette Connaughton | F | 65 | 34 jaar | |
Jennifer Herron | F | 54 | 10 jaar | |
Charles Albright | M | 66 | 12 jaar | |
Laura Bessen | M | 61 | 15 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 55 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Lynn Sadowski Mason
- Persoonlijk netwerk